Antibody-drug conjugates in breast cancer: mechanisms of resistance and future therapeutic perspectives.

IF 7.6 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2025-09-29 DOI:10.1038/s41523-025-00829-5

Irene Valle, Thomas Grinda, Lorenzo Antonuzzo, Barbara Pistilli

引用次数: 0

Abstract

Although antibody-drug conjugates (ADCs) revolutionized cancer treatment, especially in breast cancer, resistance remains a major challenge. It may involve target expression and distribution, linker stability, ADC intratumor penetration and intracellular internalization, payload activity but also interaction with the tumor microenvironment. Strategies to overcome resistance under investigation include combination therapies, novel payloads, and next-generation ADC designs. The identification of predictive biomarkers may also help guide treatment selection and prevent resistance.

查看原文本刊更多论文

乳腺癌中的抗体-药物偶联物：耐药机制和未来治疗前景。

尽管抗体-药物偶联物（adc）彻底改变了癌症治疗，特别是乳腺癌，但耐药性仍然是一个主要挑战。它可能涉及靶标表达和分布、连接体稳定性、ADC肿瘤内渗透和细胞内内化、有效载荷活性以及与肿瘤微环境的相互作用。正在研究的克服耐药性的策略包括联合治疗、新型有效载荷和下一代ADC设计。预测生物标志物的鉴定也可能有助于指导治疗选择和预防耐药性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.